Search research articles
Contact Us
Filters
Showing results (141-150 of 251) with videos related to
Page
of 26
Sort By:
Oncology
|
February 17, 2005
Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study
J-L Van Laethem, Ph Van Maele, C Verslype, et al.
British Journal of Cancer
|
May 20, 2015
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
T Macarulla, A Cervantes, J Tabernero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 27, 2013
Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology
I Borbath, A Ceratti, C Verslype, et al.
British Journal of Cancer
|
April 14, 2015
Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial
M Verstraete, A Debucquoy, J Dekervel, et al.
Oncogene
|
December 22, 1999
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor)
S Tejpar, F Nollet, C Li, et al.
Acta Gastro-Enterologica Belgica
|
May 1, 2009
Quality assurance and recommendations for quality assessment of screening colonoscopy in Belgium
E Macken, T Moreels, P Pelckmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 28, 2014
Quality assurance in the treatment of colorectal cancer: the EURECCA initiative
A J Breugom, P G Boelens, C B M van den Broek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 14, 2017
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
D Arnold, B Lueza, J-Y Douillard, et al.
ESMO Open
|
June 10, 2022
Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis
T Yoshino, E Van Cutsem, J Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 9, 2002
Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer
P Flamen, E Van Cutsem, A Lerut, et al.
Page
of 26
Search research articles
Search
Showing results (141-150 of 251) with videos related to
Sort By:
Page
of 26
Oncology
|
February 17, 2005
Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study
J-L Van Laethem, Ph Van Maele, C Verslype, et al.
British Journal of Cancer
|
May 20, 2015
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
T Macarulla, A Cervantes, J Tabernero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 27, 2013
Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology
I Borbath, A Ceratti, C Verslype, et al.
British Journal of Cancer
|
April 14, 2015
Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial
M Verstraete, A Debucquoy, J Dekervel, et al.
Oncogene
|
December 22, 1999
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor)
S Tejpar, F Nollet, C Li, et al.
Acta Gastro-Enterologica Belgica
|
May 1, 2009
Quality assurance and recommendations for quality assessment of screening colonoscopy in Belgium
E Macken, T Moreels, P Pelckmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 28, 2014
Quality assurance in the treatment of colorectal cancer: the EURECCA initiative
A J Breugom, P G Boelens, C B M van den Broek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 14, 2017
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
D Arnold, B Lueza, J-Y Douillard, et al.
ESMO Open
|
June 10, 2022
Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis
T Yoshino, E Van Cutsem, J Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 9, 2002
Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer
P Flamen, E Van Cutsem, A Lerut, et al.
Page
of 26